212 related articles for article (PubMed ID: 21434854)
21. Recent Advances in Developmental Signaling Pathway Inhibitors for the Treatment of Cancer.
Hadden MK
Curr Med Chem; 2015; 22(35):4031-2. PubMed ID: 26630931
[No Abstract] [Full Text] [Related]
22. Altered energy metabolism in cancer: a unique opportunity for therapeutic intervention.
Zhang Y; Yang JM
Cancer Biol Ther; 2013 Feb; 14(2):81-9. PubMed ID: 23192270
[TBL] [Abstract][Full Text] [Related]
23. Anticancer Effects of γ-Tocotrienol Are Associated with a Suppression in Aerobic Glycolysis.
Parajuli P; Tiwari RV; Sylvester PW
Biol Pharm Bull; 2015; 38(9):1352-60. PubMed ID: 26328490
[TBL] [Abstract][Full Text] [Related]
24. Oncogenic regulation of tumor metabolic reprogramming.
Tarrado-Castellarnau M; de Atauri P; Cascante M
Oncotarget; 2016 Sep; 7(38):62726-62753. PubMed ID: 28040803
[TBL] [Abstract][Full Text] [Related]
25. Effects of orexin A on glucose metabolism in human hepatocellular carcinoma in vitro via PI3K/Akt/mTOR-dependent and -independent mechanism.
Liu Y; Zhao Y; Guo L
Mol Cell Endocrinol; 2016 Jan; 420():208-16. PubMed ID: 26549689
[TBL] [Abstract][Full Text] [Related]
26. Clinical development of cancer therapeutics that target metabolism.
Clem BF; O'Neal J; Klarer AC; Telang S; Chesney J
QJM; 2016 Jun; 109(6):367-72. PubMed ID: 26428335
[TBL] [Abstract][Full Text] [Related]
27. Restoration of mitochondria function as a target for cancer therapy.
Bhat TA; Kumar S; Chaudhary AK; Yadav N; Chandra D
Drug Discov Today; 2015 May; 20(5):635-43. PubMed ID: 25766095
[TBL] [Abstract][Full Text] [Related]
28. Drivers of the Warburg phenotype.
Cairns RA
Cancer J; 2015; 21(2):56-61. PubMed ID: 25815844
[TBL] [Abstract][Full Text] [Related]
29. Glycometabolic adaptation mediates the insensitivity of drug-resistant K562/ADM leukaemia cells to adriamycin via the AKT-mTOR/c-Myc signalling pathway.
Zhang X; Ai Z; Chen J; Yi J; Liu Z; Zhao H; Wei H
Mol Med Rep; 2017 Apr; 15(4):1869-1876. PubMed ID: 28259993
[TBL] [Abstract][Full Text] [Related]
30. Therapeutic Potential of Small Molecule Inhibitors.
Khera N; Rajput S
J Cell Biochem; 2017 May; 118(5):959-961. PubMed ID: 27813176
[TBL] [Abstract][Full Text] [Related]
31. Reactive oxygen species regulation of autophagy in cancer: implications for cancer treatment.
Li L; Ishdorj G; Gibson SB
Free Radic Biol Med; 2012 Oct; 53(7):1399-410. PubMed ID: 22820461
[TBL] [Abstract][Full Text] [Related]
32. Effects of sorafenib on energy metabolism in breast cancer cells: role of AMPK-mTORC1 signaling.
Fumarola C; Caffarra C; La Monica S; Galetti M; Alfieri RR; Cavazzoni A; Galvani E; Generali D; Petronini PG; Bonelli MA
Breast Cancer Res Treat; 2013 Aug; 141(1):67-78. PubMed ID: 23963659
[TBL] [Abstract][Full Text] [Related]
33. Mitochondria: The metabolic switch of cellular oncogenic transformation.
Tan YQ; Zhang X; Zhang S; Zhu T; Garg M; Lobie PE; Pandey V
Biochim Biophys Acta Rev Cancer; 2021 Aug; 1876(1):188534. PubMed ID: 33794332
[TBL] [Abstract][Full Text] [Related]
34. Twist promotes reprogramming of glucose metabolism in breast cancer cells through PI3K/AKT and p53 signaling pathways.
Yang L; Hou Y; Yuan J; Tang S; Zhang H; Zhu Q; Du YE; Zhou M; Wen S; Xu L; Tang X; Cui X; Liu M
Oncotarget; 2015 Sep; 6(28):25755-69. PubMed ID: 26342198
[TBL] [Abstract][Full Text] [Related]
35. Targeting the mTOR pathway in tumor malignancy.
Cheng H; Walls M; Baxi SM; Yin MJ
Curr Cancer Drug Targets; 2013 Mar; 13(3):267-77. PubMed ID: 23297825
[TBL] [Abstract][Full Text] [Related]
36. Mitochondria and Cancer.
Zong WX; Rabinowitz JD; White E
Mol Cell; 2016 Mar; 61(5):667-676. PubMed ID: 26942671
[TBL] [Abstract][Full Text] [Related]
37. A causal link from ALK to hexokinase II overexpression and hyperactive glycolysis in EML4-ALK-positive lung cancer.
Ma Y; Yu C; Mohamed EM; Shao H; Wang L; Sundaresan G; Zweit J; Idowu M; Fang X
Oncogene; 2016 Nov; 35(47):6132-6142. PubMed ID: 27132509
[TBL] [Abstract][Full Text] [Related]
38. Interleukin-6 confers radio-resistance by inducing Akt-mediated glycolysis and reducing mitochondrial damage in cells.
Kumari N; Das A; Bhatt AN
J Biochem; 2020 Mar; 167(3):303-314. PubMed ID: 31670806
[TBL] [Abstract][Full Text] [Related]
39. INPP4B-mediated tumor resistance is associated with modulation of glucose metabolism via hexokinase 2 regulation in laryngeal cancer cells.
Min JW; Kim KI; Kim HA; Kim EK; Noh WC; Jeon HB; Cho DH; Oh JS; Park IC; Hwang SG; Kim JS
Biochem Biophys Res Commun; 2013 Oct; 440(1):137-42. PubMed ID: 24051093
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of Aerobic Glycolysis Represses Akt/mTOR/HIF-1α Axis and Restores Tamoxifen Sensitivity in Antiestrogen-Resistant Breast Cancer Cells.
Woo YM; Shin Y; Lee EJ; Lee S; Jeong SH; Kong HK; Park EY; Kim HK; Han J; Chang M; Park JH
PLoS One; 2015; 10(7):e0132285. PubMed ID: 26158266
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
